12 Best Medical Stocks to Buy Under $10
In this article, we will take a look at the 12 best medical stocks to buy under $10. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Best Medical Stock...
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
| 10.35 | |
| 10.6 | |
| - | |
| 10.6 | |
| 10.27 | |
| 4.92-21.63 | |
| 716 M | |
| 68 321 K | |
| 0 | |
| -0.82 | |
| 1.251 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
In this article, we will take a look at the 12 best medical stocks to buy under $10. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Best Medical Stock...
In this article, we will take a look at the 15 small-cap stocks with high potential. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Small-Cap Stocks w...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: